Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00232999 | Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma | PHASE2 | COMPLETED | 15 | — | — | Oct 1, 2005 | Jan 1, 2006 | Nov 12, 2021 | 3 | Canada |
| Name | Type | Description |
|---|---|---|
| Nebulized IVX-0142 | DRUG | - |
Inclusion Criteria: * Mild stable allergic asthma * Positive skin-prick test to at least one common aeroallergen * Positive methacholine challenge * Positive allergen-induced early- and late-phase airway bronchoconstriction * General good health Exclusion Criteria: * Lung diseases other than mild...